AMLX Presents ALS Trial Data
Amylyx Pharmaceuticals presents data from first-in-human, dose-ranging Phase 1 LUMINA trial of AMX0114 in ALS at ENCALS 2026
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.